📰 Multiple System News
Page 7 - Multiple System News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Multiple System. Real-time updates on events, politics, business and more.
March 31, 2022
Hospice organizations have had to redeploy workers to cover staffing gaps, offer overtime, bring in costly contingent help and even turn patients away during the pandemic.
February 8, 2022
McLean, VA (PRWEB) February 08, 2022 -- The Multiple System Atrophy Coalition started off the new year by announcing several new members to their leadership
January 28, 2022
MELBOURNE, Australia, Jan. 28, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (Alterity or the Company), a biotechnology ...
January 28, 2022
/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...
January 28, 2022
Study demonstrates reduction of a-synuclein aggregation and preservation of neurons MELBOURNE, Australia, Jan. 28, 2022 /PRNewswire/ – Alterity Therapeutics (ASX: ATH,...
December 3, 2021
Fridrik Thorsteinsson, who has MSA, is raising money to help others with the condition.
November 5, 2021
/PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying...
November 4, 2021
Colorectal impairment reversed in a preclinical model of Parkinson’s Disease ATH434 presents a novel mechanism of action for the treatment...
August 12, 2021
TORONTO and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) ("ProMIS or the Company"), a biotechnology company focused on the discovery and development
June 24, 2021
Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial Highlights: Alterity receives positive guidance from the European Medicines Agency’s Committee for Medicinal Products for Human Use on its Phase 2 clinical trial for Multiple System Atrophy. Concurrence with Alterity’s plan to target early stage MSA patients. Endorsement on selection of biomarker endpoints to assess pathological hallmarks of MSA. Agreement that ATH434 has potential...